The pharmacology of oversedation in mechanically ventilated adults

Current Opinion in Critical Care

Volumn 14, Issue 4, 2008, Pages 403-407

  Devlin, John W ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Coma; Critical care; Dexmedetomidine; Intensive care unit; Lorazepam; Midazolam; Pharmacology; Propofol; Sedation

Indexed keywords

DEXMEDETOMIDINE; LORAZEPAM; MIDAZOLAM; PROPOFOL; HYPNOTIC SEDATIVE AGENT;

ALCOHOL WITHDRAWAL; ANXIETY; ARTIFICIAL VENTILATION; CLINICAL TRIAL; COMA; CONSCIOUSNESS LEVEL; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; DELIRIUM; DRUG CLEARANCE; DRUG COST; DRUG HALF LIFE; DRUG METABOLISM; DRUG WITHDRAWAL; GENETIC POLYMORPHISM; HEALTH CARE COST; HEALTH CARE PERSONNEL; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; PARALYSIS; PHARMACOECONOMICS; PHARMACOGENETICS; REVIEW; RISK FACTOR; SEDATION; SEIZURE; SURGICAL PATIENT; INTOXICATION;

HUMANS; HYPNOTICS AND SEDATIVES; INTENSIVE CARE UNITS; OVERDOSE; RESPIRATION, ARTIFICIAL;

EID: 50349098911     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e32830280b3     Document Type: Review

References (40)

1. Sessler CN, Varney K. Patient-focused sedation and analgesia in the ICU. Chest 2008; 133:552-565.
2. Devlin JW, Nasraway SA Jr. Reversing oversedation in the intensive care unit: the role of pharmacists in energizing guideline efforts and overcoming protocol fatigue. Crit Care Med 2008; 36:626-628.
3. Ouimet S, Kavanagh BP, Gottfried SB, SkrobikY. Incidence, risk factors and consequences of ICU delirium. Intensive Care Med 2007; 33: 66-73.
4. Roberts BL, Rickard CM, Rajbhandari D, Reynolds P. Factual memories of ICU: recall at two years postdischarge and comparison with delirium status during ICU admission: a multicentre cohort study. J Clin Nurs 2007; 16:1669-1677.
5. Carson SS, Kress JP, Rodgers JE, et al. A randomized trial of intermittent lorazepam versus propofol with daily interruption in mechanically ventilated patients. Crit Care Med 2006; 34:1326-1332.
6. Fong JJ, Kanji S, Dasta JF, et al. Propofol associated with a shorter duration of mechanical ventilation than scheduled intermittent lorazepam: a database analysis using Project IMPACT. Ann Pharmacother 2007; 41:1986-1991.
7. Pandharipande PP, Pun BT, Herr DL, et al. Effect of sedation with dexmedetomidinevs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA 2007; 298:2644-2653.
8. Petty TL Suspended life or extending death? Chest 1998; 114:360-361.
9. Jacobi J, Fraser GL, Coursin DB, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med 2002; 30:119-141.
10. Payen JF, Chanques G, Mantz J, et al. Current practices in sedation and analgesia for mechanically ventilated critically ill patients: a prospective multicenter patient-based study. Anesthesiology 2007; 106:687-695. (quiz 891 -892).
11. Weinert CR, Calvin AD. Epidemiology of sedation and sedation adequacy for mechanically ventilated patients in a medical and surgical intensive care unit. Crit Care Med 2007; 35:393-401.
12. Girard TD, Kress JP, Fuchs BD, et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. Lancet 2008; 371:126-134.
13. Marshall J, Finn CA, Theodore AC. Impact of a clinical pharmacist-enforced intensive care unit sedation protocol on duration of mechanical ventilation and hospital stay. Crit Care Med 2008; 36:427-433.
14. Quenot JP, Ladoire S, Devoucoux F, et al. Effect of a nurse-implemented sedation protocol on the incidence of ventilator-associated pneumonia. Crit Care Med 2007; 35:2031-2036.
15. Ostermann ME, Keenan SP, Seiferling RA, Sibbald WJ. Sedation in the intensive care unit: a systematic review. JAMA 2000; 283:1451-1459.
16. Spina SP, Ensom MH. Clinical pharmacokinetic monitoring of midazolam in critically ill patients. Pharmacotherapy 2007; 27:389-398.
17. Bodenham A, Shelly MP, Park GR. The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients. Clin Pharmacokinet 1988; 14:347-373.
18. Mehta S, Burry L, Fischer S, et al. Canadian survey of the use of sedatives, analgesics, and neuromuscular blocking agents in critically ill patients. Crit Care Med 2006; 34:374-380.
19. Martin J, Franck M, Sigel S, et al. Changes in sedation management in German intensive care units between 2002 and 2006: a national follow-up survey. Crit Care 2007; 11:R124.
20. Masica AL, Girard TD, Wilkinson GR, et al. Clinical sedation scores as indicators of sedative and analgesic drug exposure in intensive care unit patients. Am J Geriatr Pharmacother 2007; 5:218-231.
21. Shelly MP, Mendel L, Park GR. Failure of critically ill patients to metabolise midazolam. Anaesthesia 1987; 42:619-626.
22. Bauer TM, Ritz R, HaberthurC, et al. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet 1995; 346:145-147.
23. McKenzie CA, McKinnon W, Naughton DP, et al. Differentiating midazolam over-sedation from neurological damage in the intensive care unit. Crit Care 2005; 9:R32-R36.
24. Swart EL, van Schijndel RJ, van Loenen AC, Thijs LG. Continuous infusion of lorazepam versus midazolam in patients in the intensive care unit: sedation with lorazepam is easier to manage and is more cost-effective. Crit Care Med 1999; 27:1461-1465.
25. Barr J, Zomorodi K, Bertaccini EJ, et al. A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. Anesthesiology 2001; 95:286-298.
26. Swart EL, Zuideveld KP, de Jongh J, et al. Population pharmacodynamic modelling of lorazepam- and midazolam-induced sedation upon long-term continuous infusion in critically ill patients. Eur J Clin Pharmacol 2006; 62:185-194.
27. Pandharipande P, Shintani A, Peterson J, et al. Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. Anesthesiology 2006; 104:21 -26.
28. Devlin JW, Fong JJ, Fraser GL, Riker RR. Delirium assessment in the critically ill. Intensive Care Med 2007; 33:929-940.
29. Bamgbade OA. Dexmedetomidine for peri-operative sedation and analgesia in alcohol addiction. Anaesthesia 2006; 61:299-300.
30. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348:529-537.
31. Fukasawa T, Suzuki A, Otani K. Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. J Clin Pharm Ther 2007; 32:333-341.
32. Haas CE, Kaufman DC, Jones CE, et al. Cytochrome P450 3A4 activity after surgical stress. Crit Care Med 2003; 31:1338-1346.
33. Peeters MY, Bras LJ, DeJongh J, et al. Disease severity is a major determinant for the pharmacodynamics of propofol in critically ill patients. Clin Pharmacol Ther 2008; 83:443-451.
34. Devlin JW, Fong JJ, Schumaker GL. Identifying factors that could account for differences in duration of mechanical ventilation between intermittent lorazepam- and propofol-treated patients. Crit Care Med 2006; 34:3063-3064. (author reply 3064).
35. de Wit M, Best AM, Epstein SK, Greenblatt DJ. Lorazepam concentrations, pharmacokinetics and pharmacodynamics in a cohort of mechanically ventilated ICU patients. Int J Clin Pharmacol Ther 2006; 44: 466-473.
36. Gerlach AT, Dasta JF. Dexmedetomidine: an updated review. Ann Pharmacother 2007; 41:245-252.
37. Herr DL, Sum-Ping ST, England M. ICU sedation after coronary artery bypass graft surgery: dexmedetomidine-based versus propofol-based sedation regimens. J Cardiothorac Vasc Anesth 2003; 17:576-584.
38. Dasta JF, McLaughlin TP, Mody SH, Piech CT. Daily cost of an intensive care unit day: the contribution of mechanical ventilation. Crit Care Med 2005; 33:1266-1271.
39. Cox CE, Reed SD, Govert JA, et al. Economic evaluation of propofol and lorazepam for critically ill patients undergoing mechanical ventilation. Crit Care Med 2008; 36:706-714.
40. Dasta JF, Jacobi J, Sesti AM, McLaughlin TP. Addition of dexmedetomidine to standard sedation regimens after cardiac surgery: an outcomes analysis. Pharmacotherapy 2006; 26:798-805.